Fall 2025 funding cycle: Applications available until Monday, September 29th, 2pm PT.
- Call opens: Thursday, August 28, 2025
- Deadline: Monday, September 29, 2025 (2:00 pm PST)
- Funding results: Available before end of December 2025
Amount available: $50,000 in direct costs for 1 year
Apply through the UCSF Resource Allocation Program (RAP) portal
The CFAR Mentored Scientist Award (our primary award program) is a mentoring and training grant targeted toward early stage (either at a senior stage of clinical or postdoctoral training or junior faculty) investigators at UCSF or affiliated partner institutes in the conduct of an HIV research project. These awards are designed to acquire preliminary data and research skills to prepare investigators for a future grant effort. Applicants for this award must indicate a faculty research mentor(s) who will commit to guiding the applicant throughout the duration of the proposed project.
Designation of Mentor
All Mentored award applications from individuals at the Assistant Professor level or below require an HIV research mentor. Mentors can, but are not required to, have supervisory authority over the applicant. CFAR requires your research mentor’s support to advise and guide the research portion of your application before submitting it to RAP.
Of high interest to CFAR are investigations ranging from basic pathogenesis to clinical outcomes in the research areas of HIV/aging and inflammation, latency, cure, vaccines, co-infections, HIV in women, implementation science, and research related to HIV-infected and HIV-impacted Bay Area populations. Projects must be within NIH’s HIV/AIDS research high or medium priority areas. Projects in closely related areas (e.g. TB, HCV, drug use, etc.) must be clearly linked to HIV in order to be eligible for CFAR funding.
The award amount is $50,000 in direct costs for one year.
CFAR requests that applicants review the NIAID HIV Language Guide as they prepare their proposals so that they can follow best practices on language for communicating respectfully about HIV and related topics, including the use of person-first, non-stigmatizing language. Please contact us if you have any questions about this request.
For more detailed information about this RFA, please see the RAP Portal.
To see examples of previously funded projects, see the list below.
Mentored Science Awardees
133 Awards
-
Exploring the PrEP implementation landscape in preventative health care delivery for women in two high incidence counties in Florida
Exploring the PrEP implementation landscape in preventative health care delivery for women in two high incidence counties in Florida
Abstract
This study proposes a formative qualitative investigation using focus group discussions and interviews with adult women, healthcare providers, and local stakeholders in two Florida counties with high HIV incidence. The goal is to understand communication strategies and clinical considerations related to the delivery of twice-annual injectable HIV pre-exposure prophylaxis (PrEP) within routine preventative healthcare visits. A regionally based advisory group will inform data collection priorities.
-
Modulating the Interferon Effector HELZ2 to Target HIV Persistence
Modulating the Interferon Effector HELZ2 to Target HIV Persistence
Abstract
Human Immunodeficiency Virus (HIV) remains a global health challenge despite the success of antiretroviral therapy (ART) in controlling viral replicati
-
Investigating Interleukin-2 variants to enhance the antiviral capacity of HIV-specific CD8+ T cells
Investigating Interleukin-2 variants to enhance the antiviral capacity of HIV-specific CD8+ T cells
Abstract
Human immunodeficiency virus (HIV) continues to be a significant global health issue, affecting millions worldwide.
-
Unmet need for PrEP among sero-discordant partners: Understanding barriers and facilitators to a partner-based PrEP referral program
Unmet need for PrEP among sero-discordant partners: Understanding barriers and facilitators to a partner-based PrEP referral program
Abstract
The Dominican Republic (DR) has the highest HIV prevalence of any Spanish speaking country in Latin America and the Caribbean.
-
Fill in the blank: Methodology development for antibody detection during treatment interruption.
Fill in the blank: Methodology development for antibody detection during treatment interruption.
Abstract
Developing functional human immunodeficiency virus (HIV) cure strategies remains a top priority in HIV research.
-
MIXED BARS: A MIXED Method Design for Behavioral Analysis of Risk Syndemics on Heavy Alcohol Consumption Study
MIXED BARS: A MIXED Method Design for Behavioral Analysis of Risk Syndemics on Heavy Alcohol Consumption Study
Abstract
-
Multiparametric single-cell spatial characterization of HIV-infected cells and immune responses from multiple gut compartments of people with HIV
Multiparametric single-cell spatial characterization of HIV-infected cells and immune responses from multiple gut compartments of people with HIV
Abstract
Despite its effectiveness in suppressing HIV replication, Antiretroviral therapy (ART) does not eliminate the long-lived pool of HIV reservoir cells.
-
Novel Multiplexed LC-MS/MS for Tissue Level Quantitation and Characterization of Broadly Neutralizing Anti- HIV- 1 Monoclonal Antibodies (bnAb)
Novel Multiplexed LC-MS/MS for Tissue Level Quantitation and Characterization of Broadly Neutralizing Anti- HIV- 1 Monoclonal Antibodies (bnAb)
Abstract
VRC07-523LS, a modified potent variant of bnAb VRC01 targeting the CD4 binding site of the HIV-1 envelope protein, is currently undergoing rigorous cli
-
Molecular mechanisms of patient adapted HIV-1 Vif antagonism of human APOBEC3H
Molecular mechanisms of patient adapted HIV-1 Vif antagonism of human APOBEC3H
Abstract
Polymorphisms in human APOBEC3H (A3H) affect the transmission dynamics of HIV-1, with stable and active A3H being maintained at high frequencies in pop
-
Assessing a role for the vaccinal effect in post-intervention control of HIV
Assessing a role for the vaccinal effect in post-intervention control of HIV
Abstract